<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40985135</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Percutaneous Left Atrial Appendage Closure in Patients With Cardioembolic Breakthrough Stroke: An International Observational Study.</ArticleTitle><Pagination><StartPage>e70365</StartPage><MedlinePgn>e70365</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70365</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.70365</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with non-valvular atrial fibrillation (AF) who experience an ischemic stroke despite oral anticoagulation (OAC) are at particularly high risk of recurrence, with a reported annualized ischemic stroke rate of 5.3%-8.9%. The optimal strategy for secondary prevention in these patients remains unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed all percutaneous left atrial appendage closures (LAAC) attempted in AF patients experiencing an ischemic stroke under OAC and who were prospectively collected in four European centers. All index strokes were categorized by an experienced neurologist to exclude patients with non-cardioembolic etiology or insufficient OAC. The primary endpoint was a recurrent ischemic stroke at 2&#x2009;years after the procedure. Secondary endpoints included procedure-related complications and 2-year death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 2234 patients submitted to LAAC procedure, 95 had a cardioembolic breakthrough stroke. LAAC procedures were performed at a mean of 4&#x2009;months after the breakthrough stroke. The main antithrombotic therapy at discharge (83%) and at the latest follow-up (79%) consisted of OAC. At the median follow-up of 713&#x2009;days, the primary endpoint occurred in 4 patients (4%). Procedure-related complications were rare (1%) whereas death occurred in 5% of patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">LAAC procedures were safe and feasible in patients with cardioembolic breakthrough stroke. Recurrent stroke rates were lower than those reported in previous studies with OAC continuation after breakthrough stroke, suggesting a potential additive protection by LAAC on top of OAC. Results from ongoing randomized trials are required to validate our findings.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galea</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Hospital Centre of Biel, Biel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casu</LastName><ForeName>Gavino</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical and Interventional Cardiology, University of Sassari, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bini</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School for Health Sciences, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laconi</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical and Interventional Cardiology, University of Sassari, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merella</LastName><ForeName>Pier Luigi</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0001-6758-0343</Identifier><AffiliationInfo><Affiliation>Clinical and Interventional Cardiology, University of Sassari, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chalkou</LastName><ForeName>Konstantina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Research, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preda</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Electrophysiology Unit, De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerciello</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele University Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Angelo</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-1198-9745</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele University Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bella</LastName><ForeName>Paolo Della</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele University Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzone</LastName><ForeName>Patrizio</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Electrophysiology Unit, De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auer</LastName><ForeName>Elias</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Graduate School for Health Sciences, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasys</LastName><ForeName>Antanas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seiffge</LastName><ForeName>David Julian</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Urs</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Neurology, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xe4;ber</LastName><ForeName>Lorenz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020517" MajorTopicYN="Y">Atrial Appendage</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000083242" MajorTopicYN="Y">Ischemic Stroke</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000083262" MajorTopicYN="Y">Embolic Stroke</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000097546" MajorTopicYN="N">Left Atrial Appendage Closure</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">breakthrough stroke</Keyword><Keyword MajorTopicYN="N">left atrial appendage closure</Keyword><Keyword MajorTopicYN="N">oral anticoagulation</Keyword><Keyword MajorTopicYN="N">stroke</Keyword></KeywordList><CoiStatement>R.G. is a proctor and consultant for Abbott and reports speaking honorarium from Boston Scientific and research grants from Swiss Heart Foundation. E.A. reports research funding from the Gottfried &amp; Julia Bangerter Rhyner foundation. U.F. reports research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, from Medtronic (BEYOND SWIFT, SWIFT DIRECT) and from Stryker, Rapid medical, Penumbra, Medtronic and Phenox (DISTAL), Boehringer Ingelheim (TECNO). Support of the Horton Foundation for the DO IT trial. Consultancies for Medtronic (fees paid to institution). Participation in an advisory board for AstraZeneca (former Alexion/Portola), Bayer, Boehringer Ingelheim, Biogen, AbbVie, Siemens (fees paid to institution). Member of a clinical event committee (CEC) of the COATING study (Phenox). Member of the data and safety monitoring committee (DSMB) of the TITAN, LATE_MT, IN EXTREMIS and RapidPulse trials. L.R. reports research grants to institution by Abbott&#x2010;Vascular, Boston&#x2010;Scientific, Biotronik, Heartflow, Sanofi, Regeneron. He reports speaker/consultation fees by Abbott&#x2010;Vascular, Amgen, AstraZeneca, CSL&#x2010;Behring, Canon, Occlutech, Sanofi, Vifor. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>4</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40985135</ArticleId><ArticleId IdType="pmc">PMC12455140</ArticleId><ArticleId IdType="doi">10.1111/ene.70365</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wolf P. A., Abbott R. D., and Kannel W. B., &#x201c;Atrial Fibrillation as an Independent Risk Factor for Stroke: The Framingham Study,&#x201d; Stroke 22, no. 8 (1991): 983&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">1866765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruff C. T., Giugliano R. P., Braunwald E., et&#xa0;al., &#x201c;Comparison of the Efficacy and Safety of New Oral Anticoagulants With Warfarin in Patients With Atrial Fibrillation: A Meta&#x2010;Analysis of Randomised Trials,&#x201d; Lancet 383, no. 9921 (2014): 955&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">24315724</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea R., Seiffge D., and Raber L., &#x201c;Atrial Fibrillation and Ischemic Stroke Despite Oral Anticoagulation,&#x201d; Journal of Clinical Medicine 12, no. 18 (2023): 5784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10532406</ArticleId><ArticleId IdType="pubmed">37762726</ArticleId></ArticleIdList></Reference><Reference><Citation>Stretz C., Wu T. Y., Wilson D., et&#xa0;al., &#x201c;Ischaemic Stroke in Anticoagulated Patients With Atrial Fibrillation,&#x201d; Journal of Neurology, Neurosurgery, and Psychiatry 92, no. 11 (2021): 1164&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">34446528</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeris A. A., Meinel T. R., Oehler H., et&#xa0;al., &#x201c;Aetiology, Secondary Prevention Strategies and Outcomes of Ischaemic Stroke Despite Oral Anticoagulant Therapy in Patients With Atrial Fibrillation,&#x201d; Journal of Neurology, Neurosurgery, and Psychiatry 93, no. 6 (2022): 588&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9148984</ArticleId><ArticleId IdType="pubmed">35396339</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gelder I. C., Rienstra M., Bunting K. V., et&#xa0;al., &#x201c;2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With the European Association for Cardio&#x2010;Thoracic Surgery (EACTS),&#x201d; European Heart Journal 45 (2024): 3314.</Citation><ArticleIdList><ArticleId IdType="pubmed">39210723</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe J. J., Cheung Y., Foley M., et&#xa0;al., &#x201c;Residual Risk of Recurrent Stroke Despite Anticoagulation in Patients With Atrial Fibrillation: A Systematic Review and Meta&#x2010;Analysis,&#x201d; JAMA Neurology 82, no. 7 (2025): 696&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12096328</ArticleId><ArticleId IdType="pubmed">40394992</ArticleId></ArticleIdList></Reference><Reference><Citation>Cresti A., Garc&#xed;a&#x2010;Fern&#xe1;ndez M. A., Sievert H., et&#xa0;al., &#x201c;Prevalence of Extra&#x2010;Appendage Thrombosis in Non&#x2010;Valvular Atrial Fibrillation and Atrial Flutter in Patients Undergoing Cardioversion: A Large Transoesophageal Echo Study,&#x201d; EuroIntervention 15, no. 3 (2019): e225&#x2013;e230.</Citation><ArticleIdList><ArticleId IdType="pubmed">30910768</ArticleId></ArticleIdList></Reference><Reference><Citation>Imperatore G., Lochy S., Ben Yedder M., Galea R., and Aminian A., &#x201c;Percutaneous Left Atrial Appendage Closure: Supporting Evidence, Limitations and Future Directions,&#x201d; Journal of Clinical Medicine 14, no. 7 (2025): 2300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11989772</ArticleId><ArticleId IdType="pubmed">40217750</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellinger P. D., Tsivgoulis G., Steiner T., and K&#xf6;hrmann M., &#x201c;Percutaneous Left Atrial Appendage Occlusion for the Prevention of Stroke in Patients With Atrial Fibrillation: Review and Critical Appraisal,&#x201d; Journal of Stroke 20, no. 3 (2018): 281&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6186917</ArticleId><ArticleId IdType="pubmed">30309224</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlock R. P., Belley&#x2010;Cote E. P., Paparella D., et&#xa0;al., &#x201c;Left Atrial Appendage Occlusion During Cardiac Surgery to Prevent Stroke,&#x201d; New England Journal of Medicine 384, no. 22 (2021): 2081&#x2013;2091.</Citation><ArticleIdList><ArticleId IdType="pubmed">33999547</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramovitz Fouks A., Yaghi S., Selim M. H., et&#xa0;al., &#x201c;Left Atrial Appendage Closure in Patients With Atrial Fibrillation and Acute Ischaemic Stroke Despite Anticoagulation,&#x201d; Stroke and Vascular Neurology 10, no. 1 (2025): 120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11877432</ArticleId><ArticleId IdType="pubmed">38862182</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz&#x2010;Gonzalez I., Gonz&#xe1;lez&#x2010;Ferreiro R., Freixa X., et&#xa0;al., &#x201c;Left Atrial Appendage Occlusion for Stroke Despite Oral Anticoagulation (Resistant Stroke). Results From the Amplatzer Cardiac Plug Registry,&#x201d; Revista Espa&#xf1;ola de Cardiolog&#xed;a (English ed.) 73, no. 1 (2020): 28&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">31036510</ArticleId></ArticleIdList></Reference><Reference><Citation>H. P. Adams, Jr. , Bendixen B. H., Kappelle L. J., et&#xa0;al., &#x201c;Classification of Subtype of Acute Ischemic Stroke. Definitions for Use in a Multicenter Clinical Trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment,&#x201d; Stroke 24, no. 1 (1993): 35&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">7678184</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea R., Aminian A., Meneveau N., et&#xa0;al., &#x201c;Impact of Preprocedural Computed Tomography on Left Atrial Appendage Closure Success: A Swiss&#x2010;Apero Trial Subanalysis,&#x201d; JACC. Cardiovascular Interventions 16, no. 11 (2023): 1332&#x2013;1343.</Citation><ArticleIdList><ArticleId IdType="pubmed">37316145</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea R., Bini T., Krsnik J. P., et&#xa0;al., &#x201c;Pericardial Effusion After Left Atrial Appendage Closure: Timing, Predictors, and Clinical Impact,&#x201d; JACC. Cardiovascular Interventions 17 (2024): 1295&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">38795087</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea R. R. L., Fuerholz M., H&#xe4;ner J., et&#xa0;al., &#x201c;Impact of Echocardiographic Guidance on Safety and Efficacy of Left Atrial Appendage Closure: An Observational Study,&#x201d; JACC Cardiovascular Interventions 14, no. 16 (2021): 1815&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pubmed">34412799</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea R., de Marco F., Meneveau N., et&#xa0;al., &#x201c;Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS&#x2010;APERO Randomized Clinical Trial,&#x201d; Circulation 145, no. 10 (2022): 724&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">34747186</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea R., Meneveau N., de Marco F., et&#xa0;al., &#x201c;One&#x2010;Year Outcomes After Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: A Prespecified Analysis of the SWISS&#x2010;APERO Randomized Clinical Trial,&#x201d; Circulation 149, no. 6 (2024): 484&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">37875064</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea R., Krsnik J. P., Bini T., et&#xa0;al., &#x201c;Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: A Propensity Score Matching Analysis,&#x201d; Heart Rhythm 22 (2024): 971&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pubmed">39755134</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea R. and Raber L., &#x201c;Antithrombotic Therapy After Percutaneous Left Atrial Appendage Closure: Evidence, Challenges and Future Directions,&#x201d; Reviews in Cardiovascular Medicine 24, no. 12 (2023): 343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11272845</ArticleId><ArticleId IdType="pubmed">39077095</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea R. and Raber L., &#x201c;Antithrombotic Therapy in Patients Undergoing Percutaneous Left Atrial Appendage Occlusion,&#x201d; Interventional Cardiology Clinics 13, no. 4 (2024): 543&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">39245553</ArticleId></ArticleIdList></Reference><Reference><Citation>Lip G. Y., Nieuwlaat R., Pisters R., Lane D. A., and Crijns H. J., &#x201c;Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor&#x2010;Based Approach: The Euro Heart Survey on Atrial Fibrillation,&#x201d; Chest 137, no. 2 (2010): 263&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">19762550</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian Y., O'Brien E. C., Liang L., et&#xa0;al., &#x201c;Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In&#x2010;Hospital Outcomes Among Patients With Atrial Fibrillation,&#x201d; JAMA 317, no. 10 (2017): 1057&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">28291892</ArticleId></ArticleIdList></Reference><Reference><Citation>Pracon R., Zieli&#x144;ski K., Bangalore S., et&#xa0;al., &#x201c;Residual Stroke Risk After Left Atrial Appendage Closure in Patients With Prior Oral Anticoagulation Failure,&#x201d; International Journal of Cardiology 354 (2022): 17&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">35219744</ArticleId></ArticleIdList></Reference><Reference><Citation>Margonato D., Preda A., Ingallina G., et&#xa0;al., &#x201c;Left Atrial Appendage Occlusion After Thromboembolic Events or Left Atrial Appendage Sludge During Anticoagulation Therapy: Is Two Better Than One? Real&#x2010;World Experience From a Tertiary Care Hospital,&#x201d; Journal of Arrhythmia 39, no. 3 (2023): 395&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10264741</ArticleId><ArticleId IdType="pubmed">37324751</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarnink E. W., Maarse M., Fierro N., et&#xa0;al., &#x201c;Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation Contraindication,&#x201d; JACC. Cardiovascular Interventions 17, no. 11 (2024): 1311&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">38795093</ArticleId></ArticleIdList></Reference><Reference><Citation>Maarse M., Seiffge D. J., Werring D. J., et&#xa0;al., &#x201c;Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation,&#x201d; JAMA Neurology 81, no. 11 (2024): 1150&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11420820</ArticleId><ArticleId IdType="pubmed">39374446</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiffge D. J., de Marchis G. M., Koga M., et&#xa0;al., &#x201c;Ischemic Stroke Despite Oral Anticoagulant Therapy in Patients With Atrial Fibrillation,&#x201d; Annals of Neurology 87, no. 5 (2020): 677&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383617</ArticleId><ArticleId IdType="pubmed">32052481</ArticleId></ArticleIdList></Reference><Reference><Citation>Benz A. P., Hohnloser S. H., Eikelboom J. W., et&#xa0;al., &#x201c;Outcomes of Patients With Atrial Fibrillation and Ischemic Stroke While on Oral Anticoagulation,&#x201d; European Heart Journal 44, no. 20 (2023): 1807&#x2013;1814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10411934</ArticleId><ArticleId IdType="pubmed">37038327</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K., Koga M., Lee K.&#x2010;J., et&#xa0;al., &#x201c;Atrial Fibrillation&#x2010;Associated Ischemic Stroke Patients With Prior Anticoagulation Have Higher Risk for Recurrent Stroke,&#x201d; Stroke 51, no. 4 (2020): 1150&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pubmed">32098607</ArticleId></ArticleIdList></Reference><Reference><Citation>Paciaroni M., Caso V., Agnelli G., et&#xa0;al., &#x201c;Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO&#x2010;EXTEND Study,&#x201d; Stroke 53, no. 8 (2022): 2620&#x2013;2627.</Citation><ArticleIdList><ArticleId IdType="pubmed">35543133</ArticleId></ArticleIdList></Reference><Reference><Citation>Joglar J. A., Chung M. K., Armbruster A. L., et&#xa0;al., &#x201c;2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,&#x201d; Circulation 149, no. 1 (2024): e1&#x2013;e156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11095842</ArticleId><ArticleId IdType="pubmed">38033089</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakkireddy D., Thaler D., Ellis C. R., et&#xa0;al., &#x201c;Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial,&#x201d; Circulation 144, no. 19 (2021): 1543&#x2013;1552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8570346</ArticleId><ArticleId IdType="pubmed">34459659</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiffge D. J., Cancelloni V., R&#xe4;ber L., et&#xa0;al., &#x201c;Secondary Stroke Prevention in People With Atrial Fibrillation: Treatments and Trials,&#x201d; Lancet Neurology 23, no. 4 (2024): 404&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">38508836</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>